-- Replaces Lewis T. "Rusty" Williams, M.D.,
on Board of Directors --
FOSTER
CITY, Calif., May 16, 2022
/PRNewswire/ -- Arcellx, Inc. (NASDAQ: ACLX), a biotechnology
company reimagining cell therapy through the development of
innovative immunotherapies for patients with cancer and other
incurable diseases, today announced the appointment of Olivia Ware to its Board of Directors. Ms. Ware,
a successful executive, brings a wealth of knowledge from her more
than 20 years of experience in biotech and pharmaceutical drug
development, commercialization, and healthcare management.
"On behalf of our entire Board, I'd like to thank Rusty for his
many contributions to Arcellx as both a private and publicly traded
biotech company. I've personally appreciated Rusty's leadership and
guidance and wish him all the best as he focuses on building his
new company," said Rami Elghandour,
Arcellx's Chairman and Chief Executive Officer. "Olivia's deep
industry and commercialization expertise will be an invaluable
addition to the existing depth of experience on our Board. Olivia
was an instrumental player for the launch of several of the world's
largest revenue producing oncology drugs, including
Rituxan®, Herceptin®, and
Avastin®. This experience will allow her to provide
strategic guidance as we plan to initiate a Phase 2 pivotal study
for our CART-ddBCMA program for the treatment of patients with
relapsed or refractory multiple myeloma and focus on delivering our
novel cell therapy to patients as quickly as possible. We are
excited to welcome someone of Olivia's caliber to our Board and
look forward to her contributions as we advance our novel platform
through the clinic and maximize the value of our D-Domain
technology."
"This is an exciting time to join the Arcellx Board. Arcellx's
lead product candidate, CART-ddBCMA, has the potential to be a
meaningful treatment option for patients diagnosed with multiple
myeloma, an incurable disease," said Olivia
Ware. "My passion and track record launching and building
blockbuster drug franchises comes from my dedication to serving the
needs of patients, their families, and the physicians who treat
them. I look forward to serving on the Board and providing my drug
development and commercialization expertise as the company
continues to progress its lead product candidate and development
pipeline in support of its mission of reimagining cell
therapy."
Most recently, Ms. Ware served as Senior Vice President, BTK
Franchise at Principia Biopharma which was acquired by Sanofi in
2020. Prior to that, she was the Senior Vice President for
commercial activities at Proteus Digital Health, Inc., a marketing
and strategy consultant, and Chief Commercial Officer at CytRx
Corporation. Ms. Ware served in a variety of roles of increasing
responsibility at Genentech in sales and marketing, managed care,
and leading global cross-functional teams. She currently serves on
the public boards of Revance Therapeutics, Inc. and Ambrx, Inc. Ms.
Ware holds an M.B.A. in Finance and Marketing from the University of North Carolina, Chapel Hill, and an
A.B. from Davidson College.
Ms. Ware replaces Lewis T. "Rusty" Williams, M.D., co-founder,
chairman and chief executive officer of Walking Fish Therapeutics,
who has served on Arcellx's Board of Directors since 2019.
"It has been an amazing opportunity to be part of Arcellx's
growth as it transitioned from a preclinical, private company to a
late-stage publicly traded company," said Dr. Williams. "I look
forward to following Arcellx's progress as they continue their path
toward helping patients."
About Arcellx, Inc.
Arcellx, Inc. is a clinical-stage biotechnology company reimagining
cell therapy by engineering innovative immunotherapies for patients
with cancer and other incurable diseases. Arcellx believes that
cell therapies are one of the forward pillars of medicine and
Arcellx's mission is to advance humanity by developing cell
therapies that are safer, more effective, and more broadly
accessible. Arcellx's lead product candidate, CART-ddBCMA, is being
developed for the treatment of relapsed or refractory multiple
myeloma (r/r MM) in an ongoing Phase 1 study. CART-ddBCMA has been
granted Fast Track, Orphan Drug, and Regenerative Medicine Advanced
Therapy designations by the U.S. Food and Drug Administration.
Arcellx is also advancing its dosable and controllable CAR-T
therapy, ARC-SparX, through two programs: a Phase 1 study of
ACLX-001 for r/r MM, initiated in the second quarter of 2022; and
ACLX-002 in relapsed or refractory acute myeloid leukemia and
high-risk myelodysplastic syndrome, expected to enter the clinic in
the second half of 2022.
Forward-looking Statements
This press release contains forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E of the Securities Exchange Act of 1934, as amended.
All statements in this press release that are not purely historical
are forward-looking statements, including Arcellx's expectations
regarding the timing of clinical trials for its product candidates
and the potential of its product candidates. The forward-looking
statements contained herein are based upon Arcellx's current
expectations and involve assumptions that may never materialize or
may prove to be incorrect. These forward-looking statements are
neither promises nor guarantees and are subject to a variety of
risks and uncertainties, including those set forth in Part I, Item
1A (Risk Factors) of Arcellx's Quarterly Report on Form 10-Q and in
other reports, that Arcellx may file from time to time with the
Securities and Exchange Commission. These forward-looking
statements are made as of the date of this press release, and
Arcellx assumes no obligation to update or revise any
forward-looking statements, whether as a result of new information,
future events or otherwise, except as required by law.
Investor Contact:
Myesha
Lacy
Arcellx, Inc.
ir@arcellx.com
510-418-2412
Media Contact
Andrea
Cohen
Sam Brown Inc.
andreacohen@sambrown.com
917-209-7163
View original content to download
multimedia:https://www.prnewswire.com/news-releases/arcellx-appoints-olivia-ware-to-board-of-directors-301548262.html
SOURCE Arcellx, Inc